Extrait

The primary objective is to demonstrate that the mean average change of BCVA in patients with DME treated with ranibizumab injections at the discretion of the investigator (DI) and in accordance with disease activity criteria is non-inferior to current standard of care (PRN).

Critère d'inclusion

• visual impairment due to diabetic macular edema

Liens

• euctr
• ictrp